PASG

3.9208.59%
WC

William Chou

President, CEO & Director

Dr. William Chou, M.D., Ph.D., also known as Will, has been the Chief Executive Officer and Director of Passage Bio, Inc. from October 10, 2022 and serves as its President. Dr. Chou is an accomplished executive with healthcare experience across a range of development and commercialization roles. Dr. Chou served as CEO of Aruvant Sciences, a clinical-stage biopharmaceutical company focused on developing gene therapies for rare disease. Prior to joining Aruvant, Dr. Chou served in a variety of leadership roles at Novartis, including Vice President and Global Disease Lead for Novartis' Cell and Gene Therapy where he oversaw the global commercial launch of Kymriah, the first CAR-T cell therapy. Dr. Chou led the Kymriah lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an MBA from the Yale School of Management, an MD from the University of Pittsburgh School of Medicine and an AB in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

Positions